This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
WASHINGTON — Bernie Sanders is pushing for a long Covid “moonshot.” He released a draft legislative proposal this week, a follow up to a milestone hearing in January that sounded the alarm on long Covid as a pressing public health crisis. The pitch calls for $10 billion in mandatory funding over the next decade to establish a new long Covid research program at the National Institutes of Health.
Medicare for the first time has estimated that a new Alzheimer’s treatment could cost the program billions of dollars by next year — well beyond what Wall Street or even the drug’s manufacturer have projected — according to a document obtained by STAT. Medicare’s actuaries expect the drug Leqembi , made by the Japanese drugmaker Eisai and sold in partnership with Biogen, to cost the traditional Medicare program around $550 million in 2024, and the entire Medica
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Joe McKamey, general manager at Marcrom’s Pharmacy, highlights the potential pitfalls or misconceptions that pharmacies may encounter when opening a Medicare-focused insurance agency.
It seemed as if Logan Jenner had the best possible chance for a cure. Diagnosed at age 3 with acute myeloid leukemia, an aggressive blood cancer, Logan happened to have a targetable mutation that occurs in a small minority of childhood AML cases, making it possible for him to receive a precision therapy drug that — with chemotherapy — got him to a point where he could receive a bone marrow transplant.
Ho Anh had just started working at Lemonaid Health when he was caught up in a sting. In 2017, after receiving reports about the telehealth site, an investigator for the California medical board logged on to Lemonaid using an alias. “Mark Peters” filled out a brief questionnaire about his imaginary symptoms, and Anh answered in a message: “Mark” likely had a bacterial sinus infection, the doctor said, writing a prescription for 10 days of amoxicillin.
James Shehan shares insights on the promising trends shaping the weight loss medication and how changing views of obesity could pave the way for uptake GLP-1s.
Health systems urge Congress to lay down a 'permanent roadmap' for telehealth services as clock ticks on December deadline hlandi Thu, 04/11/2024 - 11:23
The European Parliament has voted overwhelmingly to adopt legislation that is supposed to transform the way medicines are brought to market and accessed across much of Europe. But the effort — which must still be approved by the European Council — drew mixed reactions from the pharmaceutical industry and consumer groups. A key sticking point concerns data protection.
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
The decadelong decline of independent physicians rolled on in 2022 and 2023 with a new high of 77.6% doctors employed by hospitals or other corporate entities as of the new year, according to a new | Nearly 4 in 5 physicians are employed by a hospital, payer, pharmacy chain or other corporate entity as of Jan. 1, a 5.1% increase over early 2022 and a continuation of a decadelong trend, according to a new report.
On Thursday, the Federal Trade Commission took action against alcohol addiction telehealth company Monument, affirming its promise to crack down on digital health companies’ misuse of personal health data. Monument revealed health information to third parties including Meta and Google without users’ consent, the FTC alleged , while misleading users into thinking their health data was kept confidential.
Discover effective strategies to overcome barriers to healthcare providers (HCP) and patients adopting digital health initiatives like apps. Learn how to increase engagement and improve outcomes.
How would you spend $13 billion in cash? Is biotech stale? And remember Dendreon? We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. We discuss a multibillion-dollar deal from Vertex Pharmaceuticals with sweeping implications and a lengthy backstory. We also explain why gas prices are weighing on biotech, and make a surprise announcement.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
As lawmakers, biopharma companies and others try to stabilize vulnerable pharma supply chains, drug shortages have become about as bad as they’ve ever been in the U.S. | The American Society of Health-System Pharmacists has released new data showing there were 323 drugs in shortage in the U.S. as of 2024’s first quarter—the highest number recorded since ASHP began tracking shortage data back in 2001.
Novartis accelerates its protein degrader programmes by licensing a phase 3-ready prostate cancer candidate from Arvinas in a deal worth over $1 billion
As dealmaking in biopharma picks up, the CEO of eClinical Solutions sees an opportunity for clinical software companies to make acquisitions easier to close.
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Discover the latest insights and trends from BIO-Europe Spring conference, focusing on green shoots and cautious optimism in the industry. Learn about the latest funding opportunities and more.
Hospitals and health systems have kicked off the calendar year with a flurry of merger and acquisition deals reflecting several different strategic trends driving providers in 2024. | A flurry of merger and acquisition deals unveiled during Q1 2024 reflect a blend of novel and continuing strategic trends within the hospital sector, writes Kaufman Hall.
This is the online edition of Adam’s Biotech Scorecard, a new subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered every Thursday to their inbox. Good morning! The first quarter was the fourth-best quarter for biotech financing on record, according to Jefferies. But stubbornly high inflation doesn’t bode well for the interest rate cuts that the biotech market was seeking.
Accountable care organizations have sounded the alarm on billions in durable medical equipment fraud, and officials at the Centers for Medicare & Medicaid Services (CMS) said Thursday that the | Accountable care organizations have sounded the alarm on billions in durable medical equipment fraud, and officials at the Centers for Medicare & Medicaid Services said Thursday that the agency is monitoring the issue.
Hello, everyone, and how are you today? We are doing just fine, thank you, despite the cloudy skies hovering over the unusually quiet Pharmalot campus. While the sun may not be shining, we will rely on sage advice from the Morning Mayor, who reminded us that every new day should be unwrapped like a precious gift. So while you tug on the ribbon, we will brew another cup of stimulation.
After investigations into the FDA’s response to severe drug shortages and other issues, the House Committee on Oversight and Accountability finally had its long-awaited chance to grill the agency’s | FDA Commissioner Robert Califf, M.D., told lawmakers that the agency, as the "referee," needs to be given more authority in order to preemptively halt drug shortages.
The European Parliament has voted through reforms to legislation regulating the pharma sector, which the industry claims could compromise competitiveness and patient care.
The U.S. government is accusing Regeneron of deliberately using an unusual method to overcharge Medicare for the company’s popular eye drug Eylea. | The U.S. government is accusing Regeneron of deliberately using an unusual method to overcharge Medicare for the company’s popular eye drug Eylea.
Expirations of biologic patents has enabled manufacturers to enter the market and offer lower-cost alternatives of these drugs, [which has] resulted in increased competition and price pressure, driving the growth of the biosimilar market” A report published by Towards Healthcare has estimated that the global biosimilar market will value $1,26,019.67 million by 2032, at 17.6 percent CAGR between 2023 and 2032.
The pharmaceutical industry is becoming increasingly conscious of emissions and the importance of sustainable manufacturing. Globally, the pharmaceutical sector emitted around 52 megatonnes of CO 2 in 2015, the most recent period for which detailed numbers are available. 1 That’s more than the automotive sector, which released 46.4 megatonnes in the same year, and the increased demand and complexity of medicines since then will only have swollen this figure. 1 Every major pharmaceutical manufact
Embarking on a career in the nursing field later in life is an inspiring journey that many individuals choose to undertake. Whether it’s a personal passion or a long-held dream, it’s never too late to pursue a fulfilling career in healthcare. In this guide, we will answer the most common questions asked by those starting a nursing career later in life.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content